RxDoctor Payments Data

Robin Bhavsar, MD

Urology · Bryan, TXNPI 1477759215

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 40 payments — averaging $57.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$438
  • Palette Life Sciences, Inc.$381
  • Calyxo, Inc.$302
  • Neotract Inc.$209
  • Procept Biorobotics Corporation$165
  • Richard Wolf Medical Instruments Corp.$146
  • plus $667 from 15 others

What the payments were for

  • Food & beverage$2,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 35th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$202,706
Medicare patients
429
Services billed
3,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron171$109,570
GemtesaVibegron102$61,794
Mirabegron ErMirabegron53$22,102
Potassium Citrate ErPotassium Citrate57$5,196
Trospium Chloride ErTrospium Chloride23$3,954
Testosterone Cypionate73$3,887
Tamsulosin Hcl335$3,871
Oxybutynin Chloride ErOxybutynin Chloride176$3,764
Estradiol32$3,577
Trospium Chloride52$2,624
Solifenacin Succinate41$2,597
Tolterodine Tartrate ErTolterodine Tartrate36$2,183
Fesoterodine Fumarate ErFesoterodine Fumarate12$1,950
Darifenacin ErDarifenacin Hydrobromide14$1,453
Finasteride111$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$83$109,570171 claims
Sumitomo Pharma America, Inc.Gemtesa$15$61,794102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 878 urology providers in Texas.

Other urology in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →